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INTRODUCTION
Definition and classification of marginal zone B-
cell lymphomas
Marginal zone B-cell lymphoma (MZL) is a type of
lymphoma in which the cells originate from B lymphocytes
that are normally located in the “marginal zone” of the
secondary lymphoid follicles. Depending on the site of
involvement, three distinct subgroups are defined by the
WHO Classification of Tumours of Haematopoietic and
Lymphoid Tissues [1]. 
Extranodal MZL of mucosa-associated lymphoid
tissue
Extranodal MZL of mucosa-associated lymphoid tissue
(MALT lymphoma) is an extranodal lymphoma composed
of morphologically heterogeneous small B cells, including
marginal zone (centrocyte-like) cells, monocyte-like cells,
small lymphocytes, and scattered immunoblasts and
centroblast-like cells. Plasma cell differentiation occurs in
the majority of MALT lymphomas. The infiltrate occurs in
the marginal zone of reactive B-cell follicles and extends
into the interfollicular region. In the epithelial tissues, the
neoplastic cells typically infiltrate the epithelium, forming
lymphoepithelial lesions.
Splenic B-cell MZL (splenic lymphoma with circulating
villous lymphocytes)
Splenic MZL is a B-cell neoplasm composed of small
lymphocytes, which surround and replace the spleen
white pulp germinal centers, efface the follicle mantle, and
merge with a peripheral (marginal) zone of larger cells,
including scattered transformed blasts; both small and
larger cells infiltrate the red pulp. Splenic hilar lymph
nodes and the bone marrow (BM) are frequently involved;
lymphoma cells may be detected in the peripheral blood
as villous lymphocytes.
Nodal MZL
Nodal MZL is a primary nodal B-cell neoplasm.
Although it morphologically resembles the lymph nodes
seen in MZL of the extranodal or splenic type, it lacks any
signs of extranodal or splenic disease.  
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REVIEW
Marginal zone B-cell lymphoma (MZL) is the second most common subtype of non-Hodgkin’s lymphoma in
Korea (17.3%). Mucosa-associated lymphoid tissue (MALT) can develop in almost any organ as a result of
exposure to a persistent stimulus, such as chronic infection or certain autoimmune processes. Under conditions
of prolonged lymphoid proliferation, a malignant clone may emerge, which is followed by the development of a
MALT lymphoma. Whereas MALT lymphoma of the stomach is the most common and the most extensively
studied, we focus on non-gastric MZL studies conducted in Korea that highlight the most recent advances with
respect to MZL definition, etiology, clinical characteristics, natural history, treatment approaches, outcomes, and
prognostic factors. Moreover, we discuss current organ-specific considerations and controversies, and identify
areas for future research. (Korean J Intern Med 2010;25:227-236)
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REVIEWINCIDENCE OF MZL IN KOREA
MZL represents a distinct subgroup of non-Hodgkin’s
lymphoma (NHL), which is typically characterized by an
indolent clinical course and long survival time [2-4]. In
Korea, MZL comprises 17.3% of NHLs, while MALT
lymphomas account for 16.7% and nodal MZL accounts
for 0.6% of all NHLs and 23% of B-cell lymphomas [5].
MZL is the second most frequent histologic subtype after
diffuse large B-cell lymphoma (DLBCL). Every year, an
estimated 500 patients are newly diagnosed with MZL
[6]. However, the International Lymphoma Study Group
has reported that MZL comprises 8% of NHL cases. Nodal
and splenic MZL account for 16.0% and 7.6% of MZL
cases, respectively [7]. Significant variability in the
incidence of MZL has been reported for different geographic
regions. 
ETIOLOGY OF MZL
Risk factors for extranodal MZLs have been identified.
These malignancies are associated with the acquisition of
MALT in organs that normally lack organized lymphoid
tissues, e.g., the stomach, salivary glands, thyroid,
conjunctiva, skin, and other organs. The acquisition of
MALT is induced by autoimmune disease or chronic
inflammation.
The presence of Helicobacter pylori (H. pylori) [8],
Borrelia burgdorferi [9], Chlamydia psittaci (Cp) [10],
and Campylobacter jejuni [11] may be related to stomach,
skin, ocular, and intestinal MZL, respectively. Other
extranodal MZLs have been associated with a continuous
immune-triggering mechanism involving autoantigens.
Higher incidences of lymphomas of the salivary and
lachrymal glands, thyroid, and lung have been noted for
patients with Sjögren’s syndrome, Hashimoto’s thyroiditis,
and lymphoid interstitial pneumopathy, respectively
[12,13]. In two Korean studies on non-gastric MZL (NG-
MZL), Cp DNA was detected in 60% and 78%, respectively,
of patients with ocular MZL [14,15]. Associations between
other infectious organisms and MZL remain unclear,
owing to a lack of relevant data.
ORGAN DISTRIBUTION OF NG-MZL IN  KOREA
At a single center in Korea, gastric MZL accounted for
50% of all patients with MZL [16,17]. In patients with NG-
MZL, the most commonly involved sites are (in decreasing
order of frequency) the orbit and ocular adnexa (48.9%),
lymph node and lymphatic organs (17.8%), bowel (9.3%),
lungs (6.1%), thyroid (4.9%), and salivary glands (4.5%)
[18]. The organ distribution of NG-MZL varies with the
geographic region. In a European patient survey, the
salivary gland (25%), ocular and adnexa (25%), lungs
(14%), and skin (12%) were identified as the main sites of
NG-MZL [2].
CLINICAL PRESENTATION IN KOREAN STUDIES
Patients’ characteristics
In a large cohort of Korean patients with NG-MZL [18],
the overall male-to-female ratio was almost 1:1. Even
though autoimmune diseases (e.g., Hashimoto’s thyroiditis
and Sjögren’s syndrome) occur more commonly in
females, the percentages of patients with thyroid and
salivary gland MZL were lower than those presented in
the international data set; therefore, the gender ratio was
not significantly affected [2,3]. The median age of the
cohort was 49 years. The median patient age was
approximately 10 years younger. In Korea, orbital and ocular
adnexa MZL (OA-MZL) accounts for approximately 50%
of NG-MZL cases, and OA-MZL tends to be detected
early, owing to its anatomical location [18].
In these patients, B symptoms, poor performance
status, and large mass size of the lymphoma are quite rare,
being observed in < 5% of patients. Increased levels of
lactic dehydrogenase (LDH) are observed in
approximately 10% of patients, and 75% of the patients
initially present with localized disease (defined by Ann
Arbor stage I/II). BM involvement is seen in < 10% of the
patients. Approximately 90% of the patients were
categorized into the low or low-intermediate risk groups
according to the International Prognostic Index (IPI),
while 80% of the patients were categorized as being in the
low-risk group according to the Follicular Lymphoma
International Prognostic Index (FLIPI). 
In Korean MZL analysis, the principal clinical features
were limited stage, small tumor burden, excellent
performance status, and normal LDH. However, patients
with extranodal MZL and those with nodal MZL show
differences in clinical presentation. Patients with nodal
MZL are distinguished by male predominance, higher
incidence of B symptoms, BM involvement, poor
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performance status, advanced stage, and assignment to
the high-risk group according to IPI and FLIPI [18,19].
MZL TREATMENT STRATEGIES
The optimal clinical treatment for MZL remains to be
clearly defined. Antibiotic therapy, surgery, radiation,
immunotherapy, and chemotherapy, applied either singly
or in combination, have been previously employed in
clinical practice, including watchful wait.
Treatment of stage I /II NG-MZL
Localized stage MZL can be controlled with local
modalities, such as radiotherapy and/or surgery. In
retrospective study [18], of the 151 patients with stage I or
II disease, 138 (91.4%) were treated with local modalities,
such as radiation therapy or surgery, with or without
systemic chemotherapy. The overall response (OR) rate
was 98%, with 140 patients showing complete responses
(CRs) and 8 patients having partial responses (PRs).
Notably, the CR rate for patients who received
radiotherapy was 96% (108/113 patients), whereas only
66.7% (8/12) of the patients who received primary
chemotherapy achieved a CR. Locoregional recurrence
(75%) was more common than distant site recurrence in
the patients with limited-stage MZL, regardless of the
treatment modality [18,20]. The 5-year progression-free
survival (PFS) and overall survival (OS) rates were 74.7%
and 95.9%, respectively. No significant differences in
survival were observed between the patients with nodal or
extranodal MALT involvement.
Based on the clinical data obtained for the patients with
MZL in this retrospective study, local treatment/
radiotherapy should be considered the principal treatment
modality. 
Treatment of stage III/IV NG-MZL
Given the indolent natural history of MZL, less-toxic
chemotherapeutic or immunotherapeutic agents are
preferable. In this respect, considering whether anthra-
cyclines should be used in the treatment of advanced-
stage MZL is important. To date, only one retrospective
study has addressed this issue [18]. Of the 36 patients with
advanced-stage MZL who were treated with chemotherapy,
20 received a chemotherapy regimen that contained an
anthracycline. The OR rate in that study was 75%, with 17
patients having a CR and 10 patients showing a PR.
Although the CR rate was significantly higher in patients
who were treated with the anthracycline-based chemotherapy
than in those treated with a non-anthracycline-based
regimen (65% vs. 25%, p = 0.023), the PFS (p = 0.556)
and OS (p = 0.554) for these two groups were similar.
Therefore, the advantage of using anthracycline in the
treatment of advanced-stage MZL appears to be in improving
the response rate rather than having a significant impact
on survival.
Another major issue in MZL treatment is whether
rituximab confers a survival benefit in patients with
advanced disease. Based on the results of retrospective
analyses, a prospective clinical trial of rituximab-
cyclophosphamide, vincristine, and prednisolone (R-CVP)
as a first-line treatment for advanced-stage MZL was
conducted [21]. Between March 2006 and July 2008, 42
patients were enrolled in this trial at 13 institutes in Korea.
The patients received a total of 287 cycles of R-CVP
chemotherapy (median, 8 cycles/person; range, 3 to 8
cycles/person). Twenty-four patients achieved CR (60%),
11 had PR (27.5%), 4 had stable disease (10%), and 1 had
progressive disease (2.5%), yielding an OR rate of 87.5%
(95% confidence interval [CI], 77.1 to 97.9). Toxicity-
related hospitalization was required for 9 patients (22.5%)
during treatment. However, no treatment-related deaths
occurred. After a median follow-up of 30.7 months (range,
Table 1. Chemotherapies used for patients with marginal zone B-cell lymphoma in Korea 
Study Regimen Setting of  Objectives Type of study No. of  Overall RR, % PFS OS
treatment patients (CR + PR)
Kang (2010) [21] R-CVP First-line Stage III/IV MZL Prospective 41 87.5 (60 + 27.5) 3-yr: 59% 3-yr: 94%
Oh (2010) [26] Gemcitabine Salvage Relapsed MZL Prospective 12 16.7 (0 + 16.7) Median 10.2 mon None of event
Kim (2010) [15] Doxycycline First-line Stage I Ocular Retrospective 38 47 (18 + 29) 3-yr: 84% None of event
Song (2008) [40] CVP First-line Stage I/II Ocular Retrospective 21 100 (76.2 + 33.8) 5-yr: 66% None of event
RR, response rate; CR, complete response; PR, partial response; PFS, progression-free survival; OS, overall survival; R-CVP,
rituximab-cyclophosphamide, vincristine, and prednisolone; MZL, marginal zone B-cell lymphoma.11.1 to 43.8), the estimated 3-year PFS and OS rates were
59.5% and 95.0%, respectively. Although defining the
value of rituximab is difficult in a single-arm phase II trial,
the R-CVP regimen appears to be effective and well
tolerated in patients with advanced-stage MZL (Table 1). 
Treatment of relapsed/refractory NG-MZ
In patients with MZL having long survival times,
relapses are common. Overall, more than 50% of these
patients experience a relapse within 10 years [2,18,22-25].
Relapsed or refractory MZL is treated according to the
disease stage and disease location. 
In patients with stage I or II MZL, limited-stage locoregional
recurrence (up to 75%) was more commonly observed
than distant-site relapse, regardless of the radiotherapy or
chemotherapy regimen used [18,20]. Many of these
patients achieved a CR (54.1%) or a PR (18.9%) with
radiotherapy or chemotherapy. In particular, radiotherapy
resulted in a high rate of CRs (68.8%). 
Almost all of the patients who had advanced-stage
disease at relapse were treated with chemotherapy. More
than half of the patients achieved either a CR (40.9%) or
PR (13.6%). The median PFS was 34.1 months (95% CI,
11.3 to 56.9 months), and the estimated 5-year OS was
84.3%. The relevant predictive clinical factors for reduced
PFS and OS were refractory MZL and advanced relapse
MZL.
Patients with relapsed MZL tend to experience frequent
relapses and prolonged survival. Although the second PFS
period is generally shorter than the first PFS period, the
overall survival time is consistently long.
On the basis of retrospective analyses [20], salvage
gemcitabine monotherapy was used to treat relapsed/
refractory advanced-stage MZL [26]. However, this trial
was halted early because the response rate (16.7%) did not
reach the initial assumed minimal response rate at stage I
(Table 1). 
Since MZL cases tend to exhibit recurrent relapse with
long survival times, further clinical trials should be
conducted to develop a more effective and safer treatment
modality. 
PROGNOSTIC FACTORS
The IPI and FLIPI have been used as prognostic indices
for NHL and indolent lymphoma. However, MZL has a
distinctive clinical presentation and a natural course. IPI
has been used for predicting NHL prognosis [27].
However, IPI was originally designed for aggressive
lymphoma, and for low- and intermediate-risk cases, the
discriminating power of IPI is somewhat limited [28,29].
For indolent lymphoma, most patients are categorized in
the low- and intermediate-risk groups. Thus, FLIPI has
been employed for indolent lymphoma, as is the case for
follicular lymphoma (FL) [30]. Although MZL and FL
exhibit the same indolent nature, they are regarded as
distinct disease entities. In a minority of patients with
MZL, the involvement of more than four nodes has been
noted, and no definitive evidence exists concerning the
effects of low hemoglobin values on PFS and OS rates in
cases of MZL [2,31].
In a retrospective multivariate analysis of the Korean
data, nodal MZL and advanced stage were predictive of
the PFS in a multivariate analysis. With regard to OS, poor
performance status and advanced stage were introduced
as predictive factors in the multivariate analysis [18,32].
Given the indolent nature of MZL, OS may be influenced
more by comorbidity than by MZL itself. Thus, the
performance status of patients may constitute an important
factor for OS. However, the PFS was influenced by a
variety of factors associated with disease status, rather
than by patient comorbidities. 
A low percentage of MZLs (< 5% in 5 years) transform
into large-cell, aggressive lymphomas, which are predictive
of poor prognosis for MZL OS [32].
ORGAN-SPECIFIC CONSIDERATIONS OF
NG-MZL
Treatment strategies for localized OA-MZL
Of the MALT sites of NG-MZL, the OA-MZLs have been
studied the most extensively in terms of genetic changes,
etiology, and treatment (with antibiotics, chemotherapy,
or radiotherapy) in Korea. OA-MZLs present as slowly
enlarging lesions that arise from the eyelid, orbit,
lachrymal gland, or conjunctiva. OA-MZLs account for
approximately 50% of all NG-MZL cases and more than
90% of ocular lymphoma cases [33-35]. Compared to the
data sets from other countries, the Korean studies exhibit
higher rates of conjunctival involvement (up to 50% of
OA-MZLs). 
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Treatment of stage I/II OA-MZL
Radiotherapy
Localized OA-MZL can be controlled effectively using
radiotherapy, as evidenced by the four retrospective
Korean studies conducted to date [36-39] (Table 2).
Although the data were analyzed retrospectively, excellent
responses were achieved with a relatively low dosage of
radiation (median, 30.6 Gy). The CR rates ranged from
93% to 100%, and the 5-year PFS and OS rates were >
90% and > 95%, respectively. These results demonstrate
that localized OA-MZL can be controlled effectively with
low-dosage radiation, and that the benefits of
radiotherapy persist for a long time (> 5 years). 
Despite its effective local control of tumors,
radiotherapy can have ophthalmologic complications, skin
irritation or mild conjunctivitis, lens toxicity, corneal
complications, xerophthalmia, retinal complications, and
cataracts. However, in the Korean study, severe complications,
particularly cataracts (grade ≥ 3), were reported in < 5%
of the patients. Therefore, low-dosage radiotherapy
administered alone at a median level of 30.6 Gy, in
conjunction with appropriate lens shielding, may prove to
be the optimal therapeutic modality for localized OA-MZL
[38,39].
Antibiotic therapy
A correlation between Cp infection and OA-MZL has
been suggested in several previous studies. Ferreri et al.
[10] demonstrated an association between OA-MZL and
infection with Cp in Italian patients. In that study, Cp-
DNA was detected by a combination of immunohistochemistry
(using a monoclonal antibody against Cplipopolysaccharide)
and PCR analysis in 80% of 40 lymphoma samples.
Similar findings were reported in Korea, whereby Cp-
DNA was detected in 79% of patients [14]. However, Cp-
positivity has been shown to be variable in meta-analyses
of geographic regions (overall, 25%; range, 0 to   88%).
Moreover, the use of doxycycline for the eradication of
H. pylori from patients with gastric MZL remains
controversial. Only one Korean retrospective study has
been published to date [15]. In this trial, 38 patients with
newly diagnosed, localized OA-MZL received doxycycline
for 3 weeks (n = 12) or 6 weeks (n = 26). After a median
follow-up of 26.4 months, doxycycline treatment yielded
an OR rate of 47% and a 3-year time-to-treatment failure
(TTF) rate of 84%. In a multivariate analysis, absolute
lymphocytosis (odds ratio, 4.7; 95% CI, 1.1 to 20.8; p =
0.043) and non-conjunctival tumor (odds ratio, 11.8; 95%
CI, 1.1 to 122.5; p = 0.038) were identified as negative
predictors of response. Front-line doxycycline is particularly
effective in patients with localized OA-MZL with conjunctival
involvement but without absolute lymphocytosis. Cp-
DNA was noted in 15/25 (60%) patients for whom tumor
tissues were available. However, Cp-positivity was not
associated with the doxycycline response (60% vs. 60%,
p= 1.000). Considering the efficacy of doxycycline and the
indolent nature of MZL, antibiotic therapy to eradicate Cp
may represent an alternative treatment for elderly
patients with OA-MZL or a tool for use in clinical trials
(Table 1).
Chemotherapy
Despite exerting effect local control of tumors, radiotherapy
has ophthalmologic toxic side effects, which included
moderate cutaneous or conjunctiva reactions, and late
complications, such as constant cataract, xerophthalmia,
rare ischemic retinopathy, glaucoma, and corneal ulceration.
In addition to these side effects, distant site relapse is
associated with chemotherapy of localized OA-MZL.
In a retrospective analysis [40], CVP combination
chemotherapy resulted in an OR rate of 100% (CR,
76.2%). After a median follow-up of 58 months, 14/21
Table 2. Radiotherapy regimens used to treat patients with localized orbital and ocular adnexa marginal zone
B-cell lymphomas in Korea
Study No. of patients  Median gray CR, % PFS OS Complication (grade ≥ 3)
(range)
Lee (2005) [36] 29 30.6 (30.6 - 45.0) 100 3-yr: 93% 3-yr: 100% Cataract: one patient
Suh (2006) [37] 48 30.6 (5.4 - 30.6) 100 10-yr: 93% 10-yr: 87% Cataract: two patients
Nam (2009) [38] 66 30 (20 - 45) 97.5 5-yr: 92% 5-yr: 96.4% None (13 symptomatic cataracts)
Son (2010) [39] 46 30.6 (21.6 - 45.0) 93 5-yr: 93% 5-yr: 100% Cataract: two patients
Nasolachrymal duct obstruction: two patients
RT, radiotherapy; CR, complete response; PFS, progression-free survival; OS, overall survival.(66.7%) patients were free of disease, while 7 patients
showed disease progression, manifested as extra-orbital
(n = 2) or local failures (n = 5). Radiotherapy was
delivered to five patients with local failure, and these
patients subsequently achieved a CR with late
ophthalmologic complications. Tolerable adverse events
were associated with the CVP regimen. Based on these
findings, first-line CVP combination chemotherapy, in
conjunction with radiotherapy in recurrent cases, appears
to be effective and well tolerated in patients with localized
OA-MZL. To confirm the efficacy of this first-line
chemotherapy in conjunction with radiotherapy for
patients with recurrent disease, further prospective
clinical trials are needed (Table 1). 
Pulmonary MZL (P-MZL)
What is the optimal treatment modality: surgery or
chemotherapy?
Primary NHL of the lung is a very rare condition,
accounting for only 0.4% of all malignant lymphomas
[41]. MALT lymphoma is the most common subtype of
pulmonary NHL [42]. Smoking and chronic inflammatory
conditions of the lung have been identified as etiologic
agents of P-MZL [43,44]. In the Korean retrospective data
set, 63.2% of the patients had a history of smoking, which
is consistent with most reports on this type of patient
cohort. Another notable finding in the Korean study was
that 11.5% of the students had a history of tuberculosis
[45].
With regard to clinical features, approximately 50% of
the patients initially presented without any symptoms.
Lobar or segmental consolidation was the most frequently
observed feature, being detected in 68.9% of the patients
in this study. However, since P-MZL exhibits a diversity of
lung lesion patterns on computed tomography scans [46]
(i.e., nodular, consolidation, and with diffuse infiltrative
patterns), estimating diagnostically and prognostically
significant values was difficult. Based on the previous
series, common bronchofiberoscopy may be of limited
diagnostic value [43,47,48]. In the Korean retrospective
data [45], video-assisted thoracic surgery (VATS) and
direct open lobectomy were conducted for approximately
50% of the patients. However, the remaining 50% of the
patients were diagnosed using less-invasive procedures,
such as percutaneous needle aspiration and cytology
(PCNA), and bronchofiberoscopic biopsy without surgery.
This suggests that less-invasive diagnostic procedures
should be considered prior to surgery in these patients.
The optimal management of P-MZL lymphoma in
terms of surgery, chemotherapy, and radiation therapy
alone or in combination, as well as abstention from therapy,
remains to be established. From the perspective of MZL,
localized P-MZL, which is limited to one side of the lung,
may be a marker of a favorable response to local radiation
or surgery [43,44,49]. In addition, advanced or disseminated
P-MZL, which involves bilateral lungs or extrapulmonary
sites, could be controlled by chemotherapy. However, in
the lung, even though the lesions are localized, radiation
and surgical excision of segments or lobes should be
considered carefully given the risk of surgical
complications, reductions in organ function, and the
favorable clinical course of MZL itself. In the Korean data
set [45], 56 of the 61 patients were treated with surgery (n
= 22), chemotherapy (n = 28), or radiotherapy (n = 6). Of
these, 46 patients (82.1%) achieved complete or partial
remission. The median PFS was 5.6 (95% CI, 2.6 to 8.6)
years. We detected no differences between chemotherapy
and surgery in terms of PFS (p = 0.617). This was the case
for patients with either single-lobe or unilateral P-MZL.
Therefore, in those patients for whom surgery is not
required for diagnosis, to preserve lung function and avoid
the risks associated with surgery, surgery may not be the
first-choice treatment for P-MZL.
From the results of the Korean survey, P-MZL tends to
be an indolent disease, being characterized by long-term
survival with frequent relapses, similar to other MALT-
type site MZLs. To preserve lung function and limit the
risks associated with surgery, chemotherapy should be
regarded as a first-line option for the treatment of P-MZL. 
Intestinal MZL (I-MZL)
In a previous report on gastrointestinal (GI) NHL, I-
MZL accounted for 2.7% of all GI NHL cases [50]. In cases
of NG-MZL, I-MZL was noted in 1% to 5% of all cases of
extragastric MZL. The clinical presentations were similar
to those of other NG-MZL sites. I-MZL commonly
appears as an early-stage, low-risk state [2,51].
In the Korean data set [52], the small intestine was
identified as the second most common site of GI NHL
involvement, after the stomach. The most frequently
observed I-MZL involvement site was the ileocecal region
(40.7%), and rectal MZL (15%) was observed more
frequently than MZL of the colon (4%). The most
common complaints made by patients with I-MZL were
abdominal pain (62.9%), diarrhea (22.2%), and bleeding
(15%). Advanced-stage disease was observed at a higher
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frequency for I-MZL than for MZL at other sites.
Musshoff’s stages IE, IIE1, IIE2, IIIE, and IV were identified
in 44%, 15%, 11%, 7.4%, and 22% of cases, respectively. 
Approximately 71% of the patients presented with
Musshoff’s stage I-II. Considering the clinical features of
MZLs, local treatment can be regarded as the principal
treatment modality. A high CR rate was achieved with
various treatments, including local modalities. Even for
patients with advanced-stage disease, 62.5% underwent
surgery, since almost all suffered from subjective
symptoms and the small intestine and ileocecal region are
difficult regions in which to conduct endoscopic biopsy
tissue diagnoses. CR and PR were achieved in 82% and
4% of the patients, respectively. The estimated 5-year OS
and PFS rates were 86% and 54%, respectively. Stage ≥
IIE2 was identified as a poor prognostic factor for PFS and
OS. 
Regardless of stage, I-MZL can be controlled relatively
well with local or systemic treatments, as is the case with
MZL at other sites.
Nodal MZL (N-MZL)
Nodal MZL (N-MZL) is a relatively uncommon variant
of lymphoma. In previous reports, B-cell NHL incidences
of < 1% have been reported. In a recent report, N-MZL
was identified as a distinct disease entity rather than
an advanced stage of MALT-type MZL. The clinical
presentations and survival outcomes differ for these two
types of MZL [31,53,54]. 
N-MZL has an incidence of < 1% in Korea [5]. The
clinical presentation of N-MZL is slightly different from
that of MALT lymphoma. In a Korean retrospective
analysis [19], 53% of the patients had localized disease
(stages I and II), and 21.2% (7/33) had BM involvement at
presentation. B symptoms were present in only three
patients (8.3%). Most of the patients were categorized as
low or low-intermediate risk using the IPI (77.1%). A
relatively high proportion of cases of N-MZL presented
with advanced stage, poor performance status, and high
IPI and FLIPI scores, i.e., more like FL than MALT lymphoma.
Localized N-MZL was successfully treated using either
local treatment modalities (radiotherapy, surgical
resection, or chemotherapy) or systemic chemotherapy
with or without involved field radiotherapy, as in MALT
lymphoma. A majority (94.4%) of the patients with
localized disease achieved a CR after the initial treatment. 
The superiority of an anthracycline-containing regimen
for the treatment of patients with advanced N-MZL
remains a matter of controversy. Patients with disseminated
N-MZL who had primary anthracycline-based
chemotherapy were likely to achieve a CR and showed a
favorable PFS. However, no definite prolongation of OS
was observed according to the type of chemotherapy
regimen administered. The median PFS was 3.9 (95% CI,
2.9 to 5.6) years, and the estimated 5-year PFS and OS
rates were 47.2% and 82.7%, respectively. 
Splenic marginal zone B-cell lymphoma-splenic
lymphoma with circulating villous lymphocyte (S-
MZL)
In the Korean lymphoma incidence studies, S-MZL
accounted for < 1% of all MZL cases [5,18]. Why S-MZL
occurs so rarely is difficult to explain. Although splenectomy
is required for the diagnosis of S-MZL, up to two-thirds of
patients with circulating S-MZL present with circulating
villous lymphocytes having characteristic fine cytoplasmic
polar projections [55]. Almost all patients with primary S-
MZL are older than 60 years [56,57]. S-MZL presents with
massive splenomegaly coupled with abdominal
discomfort. Peripheral LN enlargement, except for splenic
hilar LN, is absent. Nearly all patients show evidence of
infiltrated BM [56,57]. 
The clinical course of S-MZL is generally indolent, with
5-year OS rates that range from 65% to 80% [56-58].
When treatment is required, it is usually because of
symptomatic splenomegaly or cytopenia. The preferred
treatment, splenectomy, results in a reduction or
disappearance of circulating tumor lymphocytes and
recovery of the lymphoma-associated cytopenia. The
benefits conferred by splenectomy often persist for several
years, and the time to the next treatment can be more
than 5 years in patients in which lymphocytosis persists
and/or progresses after splenectomy. 
Chemotherapy alone may be considered for patients
who require treatment but in whom splenectomy is
contraindicated, and also for patients who show clinical
progression after splenectomy. Alkylating agents and
fludarabine have been reported to be active, and can be
used as single agents or in combination. Rituximab, alone
or in combination with chemotherapy, has been reported
to induce responses in patients who are refractory to
standard chemotherapy [57,59,60]. Treatment of hepatitis
C virus (HCV) infection with interferon-α, alone or in
combination with ribavirin, may be helpful for patients
having splenic lymphoma with villous lymphocyte and
HCV infection [61,62].CONCLUSION
Studies on MZL in Korea may generate important
benefits in terms of diagnosis and treatment. The
relatively high incidence of MZL in Korea should provide
sufficient numbers of patients for clinical trials, and
should generate much informative data about the disease.
In planning future clinical trials of MZL, at least two
systems must first be established and implemented. The
first of these is a well organized study group. Even though
the incidence of MZL is higher in Korea than in Western
countries, the absolute numbers of newly diagnosed
patients are low. The establishment of a well organized
nationwide study group would help to overcome this
drawback. The second prerequisite is cooperation among
clinical departments, such as those in pathology, radiation
oncology, ophthalmology, and gastroenterology. All
clinical trials must include a central pathology review. In
addition, MZL entails organ-specific considerations,
which are necessary for a multidisciplinary approach to
patients with MZL.
Several key questions remain to be answered. Does the
optimal first-line treatment for localized or advanced MZL
include rituximab, chemotherapy, radiotherapy or
watchful wait? Should patients with relapsed MZL
be treated with less-toxic immunotherapy, salvage
conventional chemotherapy, radioimmunotherapy, or
high-dose chemotherapy? How we can predict the
transformation of indolent MZL to aggressive DLBCL? 
Regarding the Korean lymphoma study, if the past 5
years are collectively referred to as the “age of retrospective
data collection,” the near future will be referred to as the
“age of prospective clinical trials and translational
studies.”
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